Spots Global Cancer Trial Database for type 2 papillary renal cell carcinoma

Every month we try and update this database with for type 2 papillary renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer	NCT00541008	Kidney Cancer	sunitinib malat...	18 Years - 120 Years	UNICANCER
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	NCT00027820	Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child...	Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M...	-	Fred Hutchinson Cancer Center
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery	NCT01688973	Recurrent Renal... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Erlotinib Hydro... Laboratory Biom... Tivantinib	-	National Cancer Institute (NCI)
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer	NCT00541008	Kidney Cancer	sunitinib malat...	18 Years - 120 Years	UNICANCER
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed	NCT02761057	Locally Advance... Metastatic Papi... Stage III Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar... Unresectable Re...	Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Crizotinib Savolitinib Sunitinib Malat...	18 Years -	National Cancer Institute (NCI)
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	NCT01727089	Clear Cell Rena... Recurrent Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Anti-Endoglin C... Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	NCT01727089	Clear Cell Rena... Recurrent Renal... Stage IV Renal ... Type 1 Papillar... Type 2 Papillar...	Anti-Endoglin C... Bevacizumab Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: